13.4 Nuclear, Charitable & Specialty Pharmacy Standards

13.4 Nuclear, Charitable & Specialty Pharmacy Standards

Beyond traditional community and hospital environments, pharmacy practice encompasses highly specialized regulatory models designed to address unique therapeutic modalities, vulnerable patient populations, and high-risk medications. This section examines three critical specialized pharmacy practice frameworks under Oklahoma and federal law:

1. Nuclear Pharmacy (Class F) and radiopharmaceutical radiation safety;
2. Charitable Pharmacies operating under the Oklahoma Unused Prescription Drug Act;
3. Specialty Pharmacy Operations and FDA Risk Evaluation and Mitigation Strategies (REMS).

---

Nuclear Pharmacy Practice Standards (OAC 535:15-17)

A Nuclear Pharmacy (Class F permit) is a specialized pharmacy dedicated to the compounding, dispensing, quality control, and distribution of radiopharmaceuticals (radioactive drugs used for diagnostic imaging and targeted radiation therapy). Nuclear pharmacies operate under concurrent regulation by the Oklahoma State Board of Pharmacy (OSBP), the Oklahoma Department of Environmental Quality (DEQ), and the federal Nuclear Regulatory Commission (NRC).

Authorized Nuclear Pharmacist (ANP) Qualifications

A pharmacist cannot compound, manipulate, or dispense radiopharmaceuticals in Oklahoma without qualifying as an Authorized Nuclear Pharmacist (ANP). Under OAC 535:15-17-3 and NRC guidelines, an ANP must:

1. Hold an active, unencumbered Oklahoma pharmacist license;
2. Certification Pathway: Be certified in Nuclear Pharmacy by the Board of Pharmacy Specialties (BPS); OR
3. Training & Experience Pathway: Have completed a structured education program consisting of:
   • Minimum 200 contact hours of didactic classroom instruction in basic radioisotope handling techniques, radiation physics, instrumentation, radiation protection, mathematics of radioactivity, and radiopharmacy biology from an accredited college of pharmacy;
   • Minimum 500 hours of clinical/experiential training in nuclear pharmacy operations under the direct, personal supervision of an approved Authorized Nuclear Pharmacist.

+-----------------------------------------------------------------------------------------+
|                    AUTHORIZED NUCLEAR PHARMACIST (ANP) CREDENTIALS                      |
+-----------------------------------------------------------------------------------------+
|  Pathway A: BPS Board Certification in Nuclear Pharmacy (BCNP)                          |
|                                    -- OR --                                             |
|  Pathway B: Structured Training Program:                                                |
|             1. 200 Contact Hours of Didactic Radiopharmacy Instruction                  |
|             2. 500 Experiential Hours under an approved Authorized Nuclear Pharmacist   |
+-----------------------------------------------------------------------------------------+

Radiation Safety Equipment & Quality Assurance

Nuclear pharmacies must maintain specialized radiation containment and detection equipment:

• Lead Shielding & Fume Hoods: Compounding is performed inside dedicated lead-shielded biological safety cabinets or laminar flow radioactive fume hoods. Heavy lead bricks, lead syringe shields, and lead delivery containers ("pigs") attenuate ionizing radiation.
• Dose Calibrator: An ionization chamber used to measure the exact quantity of radioactive decay (activity) in millicuries (mCi), microcuries (µCi), or megabecquerels (MBq) prior to dispensing. Mandatory quality control testing includes:
  1. Constancy: Tested daily using long-lived reference sources (e.g., Cobalt-57, Cesium-137);
  2. Linearity: Tested quarterly across a wide range of radioactive decay;
  3. Accuracy: Tested annually against national standards;
  4. Geometry: Tested upon installation and following repair to ensure consistent readings across different vial/syringe volumes.
• Radiation Survey Meters & Area Monitors: Geiger-Mueller (GM) survey meters and scintillation wipe counters must be utilized daily to monitor cleanroom surfaces and personnel for radioactive contamination.

Radiopharmaceutical Labeling Mandates (OAC 535:15-17-5)

Because radiopharmaceuticals decay continuously over time, labeling requires dual-layer specificity distinguishing the immediate inner container from the outer lead shielding container (pig):

---

Charitable Pharmacies & The Unused Prescription Drug Act

To prevent the wasteful destruction of viable pharmaceuticals while providing life-sustaining medications to low-income populations, the Oklahoma Legislature enacted the Unused Prescription Drug Act (Title 59 O.S. § 367.1 et seq.), governed administratively under OAC Title 535:15-16.

+-----------------------------------------------------------------------------------------+
|                    OKLAHOMA UNUSED PRESCRIPTION DRUG ACT OVERVIEW                       |
+-----------------------------------------------------------------------------------------+
| Statutory Purpose   | Facilitate donation of unused, unadulterated prescription drugs   |
|                     | to medically indigent, uninsured, or underinsured Oklahomans.     |
+---------------------+-------------------------------------------------------------------+
| Eligible Donors     | Nursing homes, assisted living centers, charitable clinics,        |
|                     | pharmacies, drug wholesalers, manufacturers, and individuals.     |
+---------------------+-------------------------------------------------------------------+
| Eligible Drugs      | - Non-controlled legend drugs ONLY                                |
|                     | - Original unopened manufacturer packaging OR unit-dose blisters  |
|                     | - Intact tamper-evident seals                                     |
|                     | - Expiration date at least 30 to 90 days in the future            |
+---------------------+-------------------------------------------------------------------+
| Absolute Ban        | CONTROLLED SUBSTANCES (Schedules II - V) ARE STRICTLY PROHIBITED  |
+---------------------+-------------------------------------------------------------------+
| Financial Rules     | Medications CANNOT be sold; pharmacy may charge a nominal         |
|                     | administrative/handling fee, but cannot deny for inability to pay.|
+-----------------------------------------------------------------------------------------+

Drug Eligibility & Acceptance Criteria

1. Packaging Integrity: Medications must be in their original, unopened manufacturer packaging, or in individual unit-dose blister packaging with intact tamper-evident seals.
2. Controlled Substance Prohibition: Controlled Dangerous Substances (Schedules II, III, IV, and V) CAN NEVER be donated, accepted, or redispensed under the Unused Prescription Drug Act. Any donated controlled substances must be immediately quarantined and destroyed.
3. Storage & Stability Restrictions:
   • Drugs requiring refrigeration cannot be accepted unless donated directly by a licensed drug manufacturer, wholesale distributor, or healthcare facility that maintains certified, continuous cold-chain temperature logs.
   • Compounded preparations and investigational drugs are ineligible.
   • Drugs subject to restricted REMS distribution with individualized patient registries (e.g., isotretinoin, thalidomide) cannot be accepted.
4. Expiration Dating: Donated medications must have an expiration date that is at least 30 to 90 days in the future at the time of donation to ensure sufficient time for dispensing and patient consumption before expiration.

Patient Eligibility & Dispensing Protocols

• Medically Indigent Definition: An individual who has no prescription insurance coverage, is ineligible for Medicaid/Medicare prescription benefits, or meets state low-income poverty guidelines.
• Dispensing Fee Limitations: A charitable pharmacy cannot sell donated medications or charge for the drug product itself. The pharmacy may charge a nominal handling/dispensing fee established by Board of Pharmacy rules, but no medically indigent patient may be denied medication due to an inability to pay the fee.

---

Specialty Pharmacy & FDA REMS Programs

Specialty pharmacy practice manages medications that require specialized handling, cold-chain distribution, complex clinical monitoring, and compliance with FDA-mandated Risk Evaluation and Mitigation Strategies (REMS).

+-----------------------------------------------------------------------------------------+
|                    HIGH-YIELD FDA REMS RESTRICTED DISTRIBUTION PROGRAMS                 |
+-----------------------------------------------------------------------------------------+
| REMS Program        | Primary Clinical Risk       | Mandatory Dispensing Rules          |
+---------------------+-----------------------------+-------------------------------------+
| **iPLEDGE Program** | Severe teratogenicity       | - 2 initial negative pregnancy tests|
| (Isotretinoin)      | (craniofacial, cardiac,     | - Monthly negative pregnancy test   |
|                     | CNS birth defects)          | - Max 30-day supply; NO refills     |
|                     |                             | - 7-day pickup window for FCBP      |
|                     |                             | - Online authorization code required|
+---------------------+-----------------------------+-------------------------------------+
| **Clozapine REMS**  | Fatal severe neutropenia /  | - Certified prescribers & pharmacies|
| (Clozapine)         | agranulocytosis             | - Absolute Neutrophil Count (ANC)   |
|                     |                             |   monitoring: baseline >= 1,500/µL  |
|                     |                             | - Patient Status Verification (PSV) |
|                     |                             |   authorization code required       |
+---------------------+-----------------------------+-------------------------------------+
| **TIRF REMS**       | Fatal respiratory depression| - Opioid-tolerant cancer patients   |
| (Transmucosal       | and rapid overdose from off-| - Must be on >= 60 mg oral morphine |
| Immediate-Release   | label use in opioid-naive   |   equivalents daily for >= 1 week   |
| Fentanyl)           | individuals                 | - Certified prescribers & pharmacies|
|                     |                             | - Electronic verification per fill  |
+-----------------------------------------------------------------------------------------+

1. iPLEDGE REMS Program (Isotretinoin)

Isotretinoin is a potent oral retinoid used for severe recalcitrant nodular acne, carrying extreme teratogenic risks:

• Patient Categories: Categorizes patients into Females of Childbearing Potential (FCBP) and Patients who Cannot Become Pregnant (non-FCBP).
• FCBP Requirements: Must have two initial negative CLIA-certified laboratory pregnancy tests prior to initiating therapy and a negative pregnancy test prior to each monthly prescription, along with commitment to two concurrent forms of effective contraception or continuous abstinence.
• Dispensing Limits: Maximum 30-day supply; zero (0) refills permitted.
• Prescription Pickup Windows:
  • FCBP: Must pick up the prescription within a strict 7-day window starting on the day of the pregnancy test (Day 1 is the date of the test);
  • Non-FCBP: Must pick up within a 30-day window from the date of the clinical office examination.
• Pharmacist Verification: Before dispensing, the pharmacist must access the online iPLEDGE system, input patient identifiers, and receive a Risk Management Authorization (RMA) approval code confirming registry clearance.

2. Clozapine REMS Program (Severe Neutropenia)

Clozapine is an atypical antipsychotic for treatment-resistant schizophrenia, carrying a life-threatening risk of severe neutropenia and agranulocytosis:

• Mandatory ANC Monitoring: Dispensing is governed by the patient's Absolute Neutrophil Count (ANC) rather than total white blood cell count:
  • General Population: Baseline ANC must be ≥ 1,500/µL to initiate therapy;
  • Benign Ethnic Neutropenia (BEN): Baseline ANC must be ≥ 1,000/µL.
• Monitoring Schedule: ANC testing is required weekly for the first 6 months, every 2 weeks for months 6 to 12, and every 4 weeks (monthly) thereafter for stable patients.
• Patient Status Verification (PSV): The dispensing pharmacy must be certified in Clozapine REMS and must obtain a Patient Status Verification (PSV) or authorization code from the Clozapine REMS registry confirming an acceptable recent ANC value prior to releasing every prescription.

3. TIRF REMS Program (Transmucosal Immediate-Release Fentanyl)

TIRF formulations (e.g., Actiq lozenge, Fentora buccal tablet, Subsys sublingual spray, Lazanda nasal spray, Abstral sublingual tablet) are rapid-onset opioids designed to bypass gastrointestinal absorption:

• Strict Indication: Indicated ONLY for the management of breakthrough cancer pain in opioid-tolerant adult patients.
• Definition of Opioid Tolerance: Patients must be actively receiving around-the-clock opioid therapy consisting of at least:
  • 60 mg oral morphine daily;
  • 30 mg oral oxycodone daily;
  • 8 mg oral hydromorphone daily;
  • 25 mcg/hr transdermal fentanyl patch; or
  • An equianalgesic daily dose of another opioid for at least 1 week (7 consecutive days).
• Certification & Outpatient Ban: Prescribers, pharmacies, and patients must be certified and enrolled in TIRF REMS. Dispensing for acute pain, post-operative pain, migraine headaches, or athletic injuries in opioid-naive patients is illegal and strictly prohibited.